ENVB — Enveric Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 890821 ·
Last close
$1.41
Market Cap
$6.31M
52W High
$13.25
52W Low
$1.17
ADV30
42,182
Next earnings
—
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,027,441 -3,027,733 8,943,999 8,296,296 861,475
Mar 2026 0 — -1,633,170 -1,633,473 5,521,464 4,908,769 460,676
Dec 2025 0 — -2,193,923 -2,194,171 5,095,941 4,677,491 918,400
Sep 2025 0 — -1,873,943 -1,873,669 4,362,061 3,757,594 905,885

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,561,197
Investing CF
—
Financing CF
$14,029,704
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-24.30
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-119,507,698
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-8,728,477
Pretax Income TTM
$-8,729,046
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -8,774,448 -8,771,987 5,095,941 918,400 4,177,541 -8,141,543
Dec 2024 0 -9,632,266 -9,574,987 3,082,543 1,489,736 1,592,807 -7,726,139
Dec 2023 0 -18,296,675 -17,310,773 4,299,840 2,343,504 1,956,336 -14,094,411
Dec 2022 0 -19,961,444 -18,504,347 19,552,925 3,995,973 14,671,924 -17,146,723
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$6,540,278
NetIncome TTM
$-8,729,046
OpCashFlow TTM
—
Assets (Latest)
$8,943,999
Forward EPS
$-1.41

Peers — same industry

TickerNameMarket CapLastDaily %
TOVX Theriva Biologics, Inc. $6.42M $0.14 —
APRE Aprea Therapeutics, Inc. $6.43M $0.45 —
SNGX SOLIGENIX, INC. $6.11M $0.28 —
TPST Tempest Therapeutics, Inc. $6.54M $0.33 —
CNSP CNS Pharmaceuticals, Inc. $6.07M $4.15 —

News headlines (Yahoo Finance, 1h cache)

Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
2026-11-13 21:05 · Yahoo
Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
2026-11-04 13:00 · Yahoo
Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate
2026-10-21 12:01 · Yahoo
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
2026-10-21 12:00 · Yahoo
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
2026-09-15 12:00 · Yahoo
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 12:30 · Yahoo
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
2026-08-05 12:00 · Yahoo
Enveric Biosciences Announces Participation in 2026 BIO International Convention
2026-06-16 13:28 · Yahoo
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
2026-04-28 11:33 · Yahoo
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
2026-08-14 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.